Table 1.
Detectable neutralizing antibodies against different SARS-CoV-2 variants across study groups.
| SARS-CoV-2 variant | Number of participants with detectable neutralizing antibodies/total participants (%)a | |||
|---|---|---|---|---|
| Group 1 | Group 2 | Group 3 | ||
| SARS-CoV-2 naïve | SARS-CoV-2 experienced | |||
| Ancestral (Wuhan-Hu-1) | 22/22 (100) | 8/8 (100) | 18/18 (100) | 18/19 (94.7) |
| Beta | 16/22 (72.7) | 8/8 (100) | 16/18 (88.9) | 16/19 (84.2) |
| Gamma | 19/22 (86.3) | 8/8 (100) | 17/18 (94.4) | 17/19 (89.5) |
| Delta | 20/22 (90.9) | 8/8 (100) | 18/18 (100) | 17/19 (89.5) |
| Epsilon | 20/22 (90.9) | 8/8 (100) | 17/18 (94.4) | 17/19 (89.5) |
aGroup 1, nursing home residents fully vaccinated with the Comirnaty vaccine; Group 2, healthy individuals fully vaccinated with the Comirnaty vaccine; Group 3, unvaccinated, COVID-19 recovered individuals that required hospitalization in internal medicine or intensive care units.